Multiplicity and the Marginal Benefits of Bevacizumab in Malignant Solid Tumours

Current Oncology - Canada
doi 10.3747/co.26.4845
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

MultiMed Inc.

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy